Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.26−0.03 (-0.20%)
Close on Nov 18, 2026Market cap $82.16MP/E 3.3Yield –
Rallybio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Rallybio's operating income for the twelve months ending Sep 30, 2026 was -$24.22M. For fiscal 2025 it was -$33.06M. The highest annual figure on record is -$25.30M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.06M | – |
| FY2024 | Dec 31, 2024 | -$60.50M | – |
| FY2023 | Dec 31, 2023 | -$78.93M | – |
| FY2022 | Dec 31, 2022 | -$67.88M | – |
| FY2021 | Dec 31, 2021 | -$45.65M | – |
| FY2020 | Dec 31, 2020 | -$25.30M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.42M | – |
| Q2 FY2026 | Jun 30, 2026 | -$5.65M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.67M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.11M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.08M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.37M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.09M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.86M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.62M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.32M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.31M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.09M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.66M | – |
See a number that looks wrong?